RxDoctor Payments Data

Christine Thomas

Psychiatric/Mental Health · Lewiston, IDNPI 1922796291

Payments from drug & device makers

$945in general payments, 2019–2025

Across 36 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$252
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$198
  • Johnson & Johnson$158
  • Axsome Therapeutics, Inc.$143
  • Teva Pharmaceuticals USA, Inc.$56
  • Supernus Pharmaceuticals, Inc.$36
  • plus $101 from 4 others

What the payments were for

  • Food & beverage$945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$945 in reported general payments places this provider in the 55th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$6,880
Medicare patients
16
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate23$38,367
Invega SustennaPaliperidone Palmitate11$37,153
RexultiBrexpiprazole14$16,335
Aripiprazole42$7,012
VyvanseLisdexamfetamine Dimesylate12$4,347
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine31$3,492
Modafinil11$2,889
Duloxetine Hcl12$1,841
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$792
Prazosin Hcl34$718
Bupropion XlBupropion Hcl23$535
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$346
Buspirone Hcl40$295
Clonazepam34$154
Hydroxyzine Hcl13$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$198$38,36723 claims
Johnson & JohnsonInvega Sustenna$158$37,15311 claims
Otsuka America Pharmaceutical, Inc.Rexulti$31$16,33514 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$30$4,34712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Lewiston

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →